A Phase II Clinical and Correlative Study of BAY 43-9006 (Sorafenib) IND 69,896 in Sarcoma
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jan 2008 Status changed from recruiting to in progress according to NCT.